Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.

[1]  Zhuoli Zhang,et al.  Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis , 2021, Frontiers in Oncology.

[2]  R. Fernandes,et al.  Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. , 2020, Cancer treatment reviews.

[3]  S. Dalle,et al.  Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. , 2020, European journal of cancer.

[4]  Fengchun Zhang,et al.  Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis , 2020, BMC Medicine.

[5]  R. Garje,et al.  Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence , 2020, Cancers.

[6]  D. Schadendorf,et al.  Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo , 2020, JAMA oncology.

[7]  Douglas B. Johnson,et al.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[8]  S. Barni,et al.  Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis , 2019, Journal of immunotherapy.

[9]  A. Alfranca,et al.  Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. , 2019, European journal of cancer.

[10]  R. Chiari,et al.  Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis , 2018, Journal of Cancer Research and Clinical Oncology.

[11]  J. Sugisaka,et al.  Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. , 2018, The oncologist.

[12]  A. Diab,et al.  The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes , 2018, Journal of Immunotherapy and Precision Oncology.

[13]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[14]  Y. Koh,et al.  Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. , 2018, Lung cancer.

[15]  M. Suarez‐Almazor,et al.  Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience , 2018, Investigational New Drugs.

[16]  Tae Yong Kim,et al.  Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer , 2018, Oncoimmunology.

[17]  E. Plimack,et al.  Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. , 2017, The oncologist.

[18]  C. Nam,et al.  Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study , 2017, BMC Medical Research Methodology.

[19]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Hein Putter,et al.  Understanding Landmarking and Its Relation with Time-Dependent Cox Regression , 2016, Statistics in Biosciences.

[21]  P. Chanson,et al.  Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Soria,et al.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.

[23]  G. Gibney,et al.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.

[24]  A. Giobbie-Hurder,et al.  Challenges of guarantee-time bias. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.